1. Protein Tyrosine Kinase/RTK
  2. c-Met/HGFR
  3. Emibetuzumab

Emibetuzumab  (Synonyms: LY2875358)

目录号: HY-P99192 纯度: 95.00%
COA

Emibetuzumab (LY2875358) 是一种人源化二价 MET 抗体 (IgG4 型)。Emibetuzumab 具有较高的中和与内化活性,能有效抑制 HGF 依赖性和非依赖性 MET 通路的激活和肿瘤生长。Emibetuzumab 可用于癌症的研究。

MCE 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

我们将采用定制合成服务的方式为您快速提供所需产品和技术服务

Emibetuzumab Chemical Structure

Emibetuzumab Chemical Structure

CAS No. : 1365287-97-3

1.  客户无需承担相应的运输费用。

2.  同一机构(单位)同一产品试用装仅限申领一次,同一机构(单位)一年内

     可免费申领三个不同产品的试用装。

3.  试用装只面向终端客户

规格 价格 是否有货 数量
1 mg ¥1800
In-stock
5 mg ¥5400
In-stock
10 mg ¥8600
In-stock
50 mg   询价  
100 mg   询价  

* Please select Quantity before adding items.

Customer Review

  • 生物活性

  • 纯度 & 产品资料

  • 参考文献

生物活性

Emibetuzumab (LY2875358) is a humanized bivalent MET antibody (IgG4 type). Emibetuzumab shows high neutralization and internalization activities, resulting in inhibition of both HGF-dependent and HGF-independent MET pathway activation and tumor growth. Emibetuzumab can be used in study of cancer[1].

IC50 & Target

MET[1].

体外研究
(In Vitro)

Emibetuzumab (LY2875358) (100 nmol/L; 6 days) inhibits HGF-stimulated proliferation of H596[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay[1]

Cell Line: H596 cells (HGF-stimulated)
Concentration: 100 nmol/L
Incubation Time: 6 days
Result: Suppressed cell proliferation.
体内研究
(In Vivo)

Emibetuzumab (LY2875358) (10 mg/kg; i.v.; once a week for 5 weeks) inhibits in vivo growth of glioblastoma U87MG xenograft tumors in mice[1].
Emibetuzumab (10 or 20 mg/kg; i.v.; single) downregulates levels of MET and pMET in the tumors of mice[1].
Emibetuzumab (10 mg/kg; i.v.; once a week for 3, 5 or 6 weeks) exhibits antitumor effects on MET-amplified xenograft mouse tumor models[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Athymic nude mice (U87MG tumor xenograft model)[1].
Dosage: 10 mg/kg
Administration: Intravenous injection, once a week for 5 weeks.
Result: Demonstrated a significant inhibition of tumor growth.
Animal Model: Athymic nude mice (MKN45 xenograft tumor model)[1].
Dosage: 10 or 20 mg/kg
Administration: Intravenous injection, single.
Result: Reduced MET and pMET in the tumors by approximately 50% at both the 10 and 20 mg/kg doses by 72 hours post dose, and the reductions persisted to 14 days.
Animal Model: Athymic nude mice (MET-amplified xenograft mouse tumor models)[1].
Dosage: 10 mg/kg
Administration: Intravenous injection, once a week for 3, 5 or 6 weeks.
Result: Resulted in a marked reduction in tumor growth in the MKN45/SNU-5/EBC-1 gastric xenograft tumors.
Clinical Trial
CAS 号
性状

液体

颜色

Colorless to light yellow

运输条件

Shipping with dry ice.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

纯度 & 产品资料

纯度: 95.00%

参考文献

Emibetuzumab 相关分类

  • 摩尔计算器

  • 稀释计算器

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

质量   浓度   体积   分子量 *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

浓度 (start) × 体积 (start) = 浓度 (final) × 体积 (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

您最近查看的产品:

Your information is safe with us. * Required Fields.

   产品名称:

 

* 需求量:

* 客户姓名:

 

* Email:

* 电话:

 

* 公司或机构名称:

   留言给我们:

Bulk Inquiry

Inquiry Information

产品名称:
Emibetuzumab
目录号:
HY-P99192
需求量: